Page 138 - HIV/AIDS Guidelines

25. Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive
containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011;16(2):157-164.

26. Stuart GS, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women:
pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation
antiretroviral in Malawi. J Acquir Immune Defic Syndr. Oct 1 2011;58(2):e40-43.
27. Morrison CS, Nanda K. Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis. Jan 2012;12(1):2-3.

28. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective
cohort study. Lancet Infect Dis. Jan 2012;12(1):19-26.

29. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol. Mar 2011;65(3):302-307.
30. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal
contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. Aug
2007;197(2):144 e141-148.
31. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human
immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol. Feb 2011;204(2):126 e121-124.
32. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with
HIV/AIDS: a systematic review. AIDS. Nov 2009;23(Suppl 1):S55-67.
33. U.S. Medical Eligibility Criteria for Contraceptive Use. Recommendations and Reports June 18, 2010 / 59(RR04);1-6;
Prepared by Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion:
(http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a1.htm?s_cid=rr5904a1_e). 2010.

34. Heikinheimo O, Lahteenmaki P. Contraception and HIV infection in women. Hum Reprod Update. Mar-Apr
2009;15(2):165-176.
35. Lehtovirta P, Paavonen J, Heikinheimo O. Experience with the levonorgestrel-releasing intrauterine system among HIV-
infected women. Contraception. Jan 2007;75(1):37-39.
36. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant
women with RNA virus loads <1000 copies/ml. J Infect Dis. Feb 15 2001;183(4):539-545.
37. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus
type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. Aug 5
1999;341(6):385-393.
38. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk
of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. Aug 5 1999;341(6):394-402.
39. Gaur AH, Freimanis-Hance L, Dominguez K, et al. Knowledge and practice of prechewing/prewarming food by HIV-
infected women. Pediatrics. May 2011;127(5):e1206-1211.
40. Ickovics JR, Wilson TE, Royce RA, et al. Prenatal and postpartum zidovudine adherence among pregnant women with
HIV: results of a MEMS substudy from the Perinatal Guidelines Evaluation Project. J Acquir Immune Defic Syndr. Jul 1
2002;30(3):311-315.
41. Bardeguez AD, Lindsey JC, Shannon M, et al. Adherence to antiretrovirals among US women during and after
pregnancy. J Acquir Immune Defic Syndr. Aug 1 2008;48(4):408-417.
42. Mellins CA, Chu C, Malee K, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected
women. AIDS Care. Sep 2008;20(8):958-968.
43. Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of
adherence in postpartum HIV-infected women. Med Care. Sep 2000;38(9):911-925.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents I-22

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.